Abivax SA (ABVX) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incyte (INCY) has outperformed Abivax SA (ABVX) over the past year, gaining 32.1% versus a gain of 2.9%. Incyte is the larger company by market cap ($22.85 billion vs $7.77 billion), about 2.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | INCY |
|---|---|---|
| Share price | $89.05 | $112.75 |
| Market cap | $7.77B | $22.85B |
| 1-day change | +2.34% | -0.61% |
| YTD return | -33.97% | +14.15% |
| 1-year return | +2.94% | +32.06% |
| 5-year return | — | +71.98% |
| P/E ratio (TTM) | — | 14.36 |
| Forward P/E | — | 12.89 |
| EPS (TTM) | $-6.08 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.14B |
| Revenue growth (YoY) | — | +21.22% |
| Net income (latest FY) | — | $1.29B |
| Gross margin | — | 92.76% |
| Operating margin | — | 29.46% |
| Net margin | — | 25.03% |
| 52-week high | $148.83 | $132.60 |
| 52-week low | $69.81 | $82.82 |
| Distance from 52-week high | -40.17% | -14.97% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +84.17% | +14.53% |
| Average volume | 1.11M | 1.63M |
| Shares outstanding | 87.27M | 202.70M |
| Employees | 98 | 2,844 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 2.9 times larger than Abivax SA by market value ($22.85B vs $7.77B).
- INCY has outperformed ABVX by 29.1 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Healthcare · Biotechnology · 98 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Healthcare · Biotechnology · 2,844 employees
ABVX vs INCY FAQ
Which is bigger, Abivax SA or Incyte?
Incyte (INCY) is larger, with a market capitalization of $22.85B compared with $7.77B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or INCY?
INCY returned +32.06% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Incyte in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.